Total Neoadjuvant Approach for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma-UK Tertiary Cancer Centre Experience.

Cancers (Basel) · 2026 · PMC13205041 · PMID 42192957

Europe PMC DOI

hedged sentence

0.0950

closest p · 1.9× alpha

0.0950

boldest claim

The sentences

did not reach statistical significancep = 0.095so close (0.05 < p ≤ 0.1)

When stratified by treatment modality, recurrence occurred more frequently in patients who received neoadjuvant SACT only, although this difference did not reach statistical significance (85.7% vs. 52.4%; Table 5 , p = 0.095).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.